Our Take
The statistical significance claim lacks specifics, but ASCO acceptance and analyst predictions of 2-3 month progression delay suggest meaningful benefit in a large patient subset.
Why it matters
PIK3CA mutations drive an estimated 40% of hormone-positive, HER2-negative breast cancers (company data). Current approved drugs cause significant side effects that limit use.
Do this week
Oncologists: Review your PIK3CA-positive breast cancer patients before July 17 FDA decision so you can plan treatment sequencing if gedatolisib wins broader approval.
Gedatolisib hits statistical significance in PIK3CA subset
Celcuity reported Friday that gedatolisib combinations delayed disease progression versus Novartis' Piqray plus hormone therapy in breast cancer patients with PIK3CA gene mutations. The company called the improvement "statistically significant and clinically meaningful" but provided no specific numbers (company announcement).
The results come from the same Phase 3 trial that previously showed benefit in patients without confirmed PIK3CA mutations, leading to Celcuity's current FDA filing. The agency's decision is expected by July 17. Celcuity plans to submit the new PIK3CA data in a supplemental application for broader approval.
Shares jumped 18% Monday, pushing market value past $7 billion (company-reported). The data will be presented at the American Society of Clinical Oncology meeting starting May 29.
PIK3CA represents large patient population with limited options
PIK3CA alterations appear in roughly 40% of hormone receptor positive, HER2-negative breast tumors (company estimate). Three approved treatments target this pathway: Novartis' Piqray, Roche's Itovebi, and AstraZeneca's Truqap. All cause problematic side effects including skin rashes, gastrointestinal issues, and hyperglycemia that reduce physician adoption.
Jefferies analyst Maury Raycroft noted that statistical significance in the two-drug combination suggests "at least a two- to three-month separation from the control arm" (analyst estimate). Leerink Partners analyst Andrew Berens said ASCO's late acceptance of the data "bodes well for the magnitude of benefit."
Approval timing creates treatment planning window
The July 17 FDA decision date gives oncologists roughly 10 weeks to assess current PIK3CA-positive patients. If approved broadly, gedatolisib could offer an alternative to existing therapies with their known toxicity profiles.
The ASCO presentation May 29-June 2 should provide the missing specifics on progression-free survival benefit. Multiple companies are developing competing PIK3CA inhibitors, making this a crowded but validated target with significant commercial potential.